Vorinostat has been shown to increase the susceptibility of CD4+ T cells to infection by HIV in a dose- and time-dependent manner, does not enhance viral fusion with cells, but increases reverse transcription, nuclear import, and integration, and enhances viral production in a spreading-infection assay. The gene discussed is CD4; the disease is infection.